We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$60.9M
Cap. Flow
+$27.1M
Cap. Flow %
5.19%
Top 10 Hldgs %
45.15%
Holding
120
New
43
Increased
21
Reduced
16
Closed
38

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$22.2M
2
BHVN icon
Biohaven
BHVN
+$17.4M
3
MBX
MBX Biosciences
MBX
+$14.3M
4
CGON icon
CG Oncology
CGON
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.9M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$28.9M
2
ACLX
Arcellx
ACLX
+$21.7M
3
TWST icon
Twist Bioscience
TWST
+$21.3M
4
TERN
Terns Pharmaceuticals
TERN
+$17.6M
5
ROIV icon
Roivant Sciences
ROIV
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KTTA icon
101
Pasithea Therapeutics
KTTA
$15M
– –
-355,082
Closed -$458K
LEGN icon
102
Legend Biotech
LEGN
$4.31B
– –
-73,328
Closed -$1.59M
LLY icon
103
Eli Lilly
LLY
$1.05T
– –
-4,759
Closed -$5.11M
MDGL icon
104
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-17,736
Closed -$10.3M
MGTX icon
105
MeiraGTx Holdings
MGTX
$1.15B
– –
-287,689
Closed -$2.29M
MLTX icon
106
MoonLake Immunotherapeutics
MLTX
$1.64B
– –
-348,401
Closed -$4.59M
NKTR icon
107
Nektar Therapeutics
NKTR
$2.31B
– –
-178,274
Closed -$7.54M
OCUL icon
108
Ocular Therapeutix
OCUL
$1.96B
– –
-522,693
Closed -$6.35M
PALI icon
109
Palisade Bio
PALI
$342M
– –
-4,192,375
Closed -$9.85M
QNCX icon
110
Quince Therapeutics
QNCX
$18.5M
– –
-3,696
Closed -$2.48M
RGEN icon
111
Repligen
RGEN
$8.31B
– –
-15,707
Closed -$2.57M
RYTM icon
112
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-58,915
Closed -$6.31M
TERN
113
DELISTED
Terns Pharmaceuticals
TERN
– –
-429,198
Closed -$17.6M
TRVI icon
114
Trevi Therapeutics
TRVI
$2.71B
– –
-399,557
Closed -$5M
TSHA icon
115
Taysha Gene Therapies
TSHA
$1.71B
– –
-182,130
Closed -$1M
VNDA icon
116
Vanda Pharmaceuticals
VNDA
$327M
– –
-58,989
Closed -$520K
VRDN icon
117
Viridian Therapeutics
VRDN
$1.99B
– –
-154,320
Closed -$4.8M
XLO icon
118
Xilio Therapeutics
XLO
$58.4M
– –
-145,002
Closed -$1.3M
BBOT
119
BridgeBio Oncology
BBOT
$686M
– –
-86,517
Closed -$1.08M
MAZE
120
Maze Therapeutics
MAZE
$1.56B
– –
-125,877
Closed -$5.22M
1 2 3 4
5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Stempoint Capital held 120 positions worth $522M, down 10% from $583M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Stempoint Capital deployed $27.1M of net new capital in Q1 2026, opening 43 new positions and adding to 21 existing holdings. Its largest new stake was Biohaven: 1,594,491 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $21.3M trimmed.

  • Stempoint Capital's largest Q1 2026 buy was Biohaven: 1,594,491 shares worth $13.5M.
  • Stempoint Capital added most to Revolution Medicines in Q1 2026, an estimated $22.2M increase.
  • Stempoint Capital's biggest Q1 2026 reduction was Twist Bioscience, cutting an estimated $21.3M.
  • Stempoint Capital fully exited Centessa Pharmaceuticals in Q1 2026, selling an estimated $28.9M.
  • Stempoint Capital's ten largest holdings make up 45% of its $522M portfolio in Q1 2026.
  • Stempoint Capital opened 43 new positions and closed 38 in Q1 2026.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $522M.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.